lifestyle.thedishh.com

Author: NOVO NORDISK INC.

Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026

April 2, 2026
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access

February 24, 2026
Novo Nordisk takes the field at the big game, putting Wegovy® pill in consumers’ hands

February 7, 2026
Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America

January 8, 2026
Novo Nordisk unveils the inaugural State of Weight and Health Report™, offering new insights that shed light on America’s obesity epidemic

January 6, 2026
FDA approves Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults

December 22, 2025
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management

December 20, 2025
Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg

November 27, 2025
Novo Nordisk’s CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®

November 14, 2025
Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors

November 8, 2025